文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症神经外科患者万古霉素血清谷浓度影响因素分析

[Analysis of influencing factors of trough serum vancomycin concentrations in critically ill neurosurgical patients].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2019-01-01
一句话结论神经外科ICU患者按标准剂量给药后仅17.9%首次谷浓度达标,年龄、多种合并症和利尿剂使用影响谷浓度。

该回顾性研究纳入2017年11月至2019年7月中山大学附属第一医院神经外科ICU的28例成人患者,共81组万古霉素谷浓度数据。初始日剂量2.00 g/d,首次谷浓度仅17.9%(5/28)达目标15-20 mg/L,71.4%偏低;全部监测中仅30.9%(25/81)达标。多因素分析显示年龄每增加1岁谷浓度升高0.14 mg/L(95%CI 0.06-0.22),合并高血压、糖尿病和冠心病者较无合并症者升高7.22 mg/L(95%CI 2.08-12.36),使用利尿剂者升高2.78 mg/L(95%CI 0.20-5.35)。

要点

  • 神经外科ICU患者按标准剂量万古霉素给药后,首次谷浓度仅17.9%(5/28)达15-20 mg/L目标,71.4%(20/28)低于治疗水平。
  • 全部81组谷浓度中仅30.9%(25/81)达标,49.4%(40/81)偏低,19.7%(16/81)偏高。
  • 年龄每增加1岁,万古霉素谷浓度升高0.14 mg/L(95%CI 0.06-0.22)。
  • 合并高血压、糖尿病和冠心病者较无合并症者谷浓度升高7.22 mg/L(95%CI 2.08-12.36)。
  • 使用利尿剂者较未使用者谷浓度升高2.78 mg/L(95%CI 0.20-5.35)。

适用人群与场景

  • 2017年11月至2019年7月中山大学附属第一医院神经外科ICU收治的成人患者,接受万古霉素治疗且至少有一次合适的谷浓度监测。

诊断标准与关键阈值

  • 万古霉素目标谷浓度为15-20 mg/L;低于该范围为低于治疗水平,高于该范围为高于治疗水平。

处置流程与药物剂量

  • 万古霉素初始日剂量为2.00(2.00,2.00)g/d,给药4-6次后首次采血测谷浓度。
  • 万古霉素疗程为8.0(6.0,15.0)天,平均日剂量2.00(1.75,3.00)g/d。

研究设计与关键结果

  • 回顾性研究,纳入28例患者共81组万古霉素谷浓度数据;初始日剂量2.00 g/d,给药4-6次后首次谷浓度10.99(6.98,16.25)mg/L,仅17.9%(5/28)达15-20 mg/L目标,71.4%(20/28)低于治疗水平,10.7%(3/28)高于治疗水平。
  • 全部监测中,平均日剂量2.00(1.75,3.00)g/d时仅30.9%(25/81)达目标谷浓度,49.4%(40/81)低于治疗水平,19.7%(16/81)高于治疗水平。
  • 不同谷浓度组间年龄、合并症、万古霉素剂量、利尿剂使用和甘露醇剂量等存在显著差异。
  • 多因素线性回归显示:年龄每增加1岁谷浓度升高0.14 mg/L(95%CI 0.06-0.22);合并高血压、糖尿病和冠心病者较无合并症者升高7.22 mg/L(95%CI 2.08-12.36);使用利尿剂者较未使用者升高2.78 mg/L(95%CI 0.20-5.35);其他变量效应无统计学意义。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,神经外科ICU患者按标准剂量万古霉素给药后目标谷浓度不常达到;年轻患者谷浓度偏低,使用利尿剂和合并多种合并症者谷浓度偏高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate trough serum vancomycin concentrations and identify their influencing factors in critically ill neurosurgical patients.

METHODS: A retrospective study was conducted. Adult patients who received vancomycin with at least one appropriate monitoring of trough serum vancomycin concentration and admitted to neurosurgical intensive care unit (ICU) of the First Affiliated Hospital of Sun Yat-sen University from November 2017 to July 2019 were enrolled. General information including gender, age, comorbidities, etc., trough serum vancomycin concentrations, vancomycin dosage, duration of vancomycin therapy, urine output, serum creatinine (SCr), concurrent medications (including mannitol,diuretic, vasopressors, non-steroidal anti-inflammatory drugs, polymyxin, aminoglycosides and contrast medium, etc.) were collected for analysis. Trough serum vancomycin concentrations were evaluated and their influencing factors were analyzed by multiple linear regression method.

RESULTS: In total, 81 trough serum vancomycin concentration data sets obtained from 28 patients were evaluated. (1) The initial daily dose of vancomycin was 2.00 (2.00, 2.00) g/d. After 4-6 doses, the trough serum vancomycin concentration obtained from initial blood draw was 10.99 (6.98, 16.25) mg/L, of which only 17.9% (5/28) achieving targeted concentrations (15-20 mg/L), 71.4% (20/28) subtherapeutic level and 10.7% (3/28) supratherapeutic level. (2) The duration of vancomycin therapy was 8.0 (6.0, 15.0) days. With average daily dose of 2.00 (1.75, 3.00) g/d, targeted trough vancomycin concentrations were achieved in only 30.9% (25/81) of all cases, subtherapeutic concentrations in 49.4% (40/81) and supratherapeutic concentrations in 19.7% (16/81). (3) There were significant differences in age, comorbidities, vancomycin dosage, diuretics use and mannitol dosage, etc. among different vancomycin concentration groups. Multiple linear regression analysis suggested that the trough serum vancomycin concentration increased by 0.14 mg/L [95% confidence interval (95%CI) was 0.06-0.22] for every 1 year increase in age, increased by 7.22 mg/L (95%CI was 2.08-12.36) in patients with multiple comorbidities (concomitant hypertension, diabetes and coronary heart disease) compared with those without comorbidities, increased by 2.78 mg/L (95%CI was 0.20-5.35) in patients treated with diuretics compared with those without diuretics. The effect of other variables was not statistically significant. It suggested that age, multiple comorbidities (concomitant hypertension, diabetes and coronary heart disease), and diuretic usage affected trough serum vancomycin concentrations.

CONCLUSIONS: Targeted trough serum vancomycin level is not often achieved in neurosurgical ICU patients following standard dosing. Younger patients are associated with lower trough serum vancomycin concentrations, while diuretic usage, combined with multiple comorbidities are associated with higher trough serum vancomycin concentrations.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yao M, Li J, Shi L, et al. [Analysis of influencing factors of trough serum vancomycin concentrations in critically ill neurosurgical patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31898570. doi:10.3760/cma.j.issn.2095-4352.2019.11.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。